Reactivation of Thyroid Eye Disease: Incidence, Timing and Clinical Phenotype
Clinical & Experimental Ophthalmology · 2026-11 · 54 (8) · 1020-1028
DOI: 10.1111/ceo.70160 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical & Experimental Ophthalmology, online erschienen am 21.08.2026. Verfasst von Hannah A McDonald und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Royal Melbourne Hospital, Parkville, Victoria, Australia. Hauptthemen laut MEDLINE: Graves Ophthalmopathy. Die Arbeit nennt 27 Literaturangaben.
Abstract (Originalsprache)
Background
Thyroid eye disease (TED) is an immune‐mediated orbitopathy with an active inflammatory phase followed by quiescence. Reactivation after apparent quiescence is recognised but poorly characterised. We aimed to describe the incidence, timing, and phenotype of TED reactivation and explore potential risk factors and triggers.
Methods
Retrospective cohort study of 727 consecutive patients with TED (2015–2025). Reactivation was defined as new or worsening TED after ≥ 1 year of documented inactivity. Data included demographics, smoking status, interval from quiescence, phenotype, severity (EUGOGO), suspected precipitants, imaging, and treatment.
Results
Twenty‐eight patients met reactivation criteria (3.9%, 95% CI 2.7%–5.5%), accounting for 29 episodes (one patient had two). Most were female (75%, 21/28). Mean age at reactivation was 60.2 ± 15.5 years (range 29–86); 75.9% of episodes occurred in patients ≥ 50 years (22/29). Median interval from quiescence to reactivation was 5 years (IQR 3–10, range 1–47). Extraocular muscle involvement occurred in 27/29 episodes (93.1%). Severity was mild (13/29, 44.8%), moderate‐to‐severe (12/29, 41.4%), or sight‐threatening (4/29, 13.8%). Clear triggers were rare; thyroid dysfunction or positive thyroid antibodies were documented in 15/29 (51.7%). Management (recorded for 28 episodes) ranged from conservative care (15/28, 53.6%) to systemic corticosteroids (7/28, 25%), with less frequent immunomodulatory therapy ( n = 3), orbital decompression ( n = 3), and radiotherapy ( n = 3).
Conclusions
TED reactivation occurred in 3.9% of patients, often within 5 years of quiescence, typically beyond the fifth decade, and most commonly with a muscle‐predominant phenotype.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ophthalmology, Royal Melbourne Hospital, Parkville, Victoria, Australia.
- Orbital, Plastics and Lacrimal Unit, Royal Victorian Eye and Ear Hospital, East Melbourne, Victoria, Australia.
- Centre for Eye Research Australia, East Melbourne, Victoria, Australia.
- Department of Surgery, Austin Health, University of Melbourne, Parkville, Victoria, Australia.
- Department of Surgery, Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, Australia.
ORCID-Profile: Hannah A McDonald
Zitieren
APA
McDonald, H. A., Khong, J. J., McNab, A. A., & Hardy, T. G. (2026). Reactivation of Thyroid Eye Disease: Incidence, Timing and Clinical Phenotype. Clinical & Experimental Ophthalmology, 54(8), 1020-1028. https://doi.org/10.1111/ceo.70160
Vancouver
McDonald HA, Khong JJ, McNab AA, Hardy TG. Reactivation of Thyroid Eye Disease: Incidence, Timing and Clinical Phenotype. Clinical & Experimental Ophthalmology. 2026;54(8):1020-1028. doi:10.1111/ceo.70160
BibTeX
@article{McDonald2026,
author = {McDonald, Hannah A and Khong, Jwu-Jin and McNab, Alan A and Hardy, Thomas G},
title = {Reactivation of Thyroid Eye Disease: Incidence, Timing and Clinical Phenotype},
journal = {Clinical & Experimental Ophthalmology},
year = {2026},
volume = {54},
number = {8},
pages = {1020--1028},
doi = {10.1111/ceo.70160}
}
EUVIMED